Imatinib Mesylate Tablet, Film Coated
Product Images NDC 47335-475

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 47335-475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-structure (Imatinib Structure)

Chemical structure of imatinib mesylate, showing the molecular arrangement including multiple aromatic rings, nitrogen-containing heterocycles, and the mesylate group (CH3SO3H).*

FDA Label Image

Spl Imatinib 100 mg

Label for Imatinib Mesylate Tablets 100 mg, film-coated oral tablets. The label states each tablet contains imatinib mesylate equivalent to 100 mg of imatinib free base. It includes dosage storage instructions, manufacturer name Sun Pharmaceutical Industries, Inc., and package size of 90 tablets. The label features a barcode and the Rx only designation.*

FDA Label Image

Spl-imatinib-100 (Spl Imatinib 100)

Label for Imatinib Mesylate Tablets 100 mg film-coated tablets, manufactured and distributed by Sun Pharmaceutical Industries, Inc. The label indicates a container size of 90 tablets, with storage instructions and a barcode. The label notes the dosage strength and dispensing details.*

FDA Label Image

Spl Imatinib 400 mg

Imatinib Mesylate Tablets 400 mg film-coated tablet label from Sun Pharmaceutical Industries, Inc. The label includes dosage strength, storage instructions between 20° to 25°C, a 30-tablet count, and distributor and manufacturer information for Sun Pharmaceutical.*

FDA Label Image

Spl-imatinib-400 (Spl Imatinib 400)

Label for Imatinib Mesylate Tablets 400 mg by Sun Pharmaceutical Industries, Inc. The label indicates oral film-coated tablets, package contains 30 tablets, with storage instructions and a barcode. Manufactured and distributed by Sun Pharma in Cranbury, NJ.*

FDA Label Image

Spl Imatinib Fig 3

A Kaplan-Meier survival curve comparing the probability of being alive and recurrence-free over time in months between patients treated with imatinib 400 mg and placebo. The graph shows separate survival trend lines with censored data points indicated, along with a table listing the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Spl Imatinib Fig 4

A Kaplan-Meier survival curve chart showing the probability of recurrence-free survival over time in months for patients treated with imatinib mesylate. Two curves compare survival probabilities at 12 months and 36 months treatment durations, with censored observations marked along the lines. The chart includes hazard ratio and confidence interval data along with numbers at risk and event counts over time.*

FDA Label Image

Spl Imatinib Fig 5

A Kaplan-Meier survival curve comparing the probability of overall survival over time in months for two imatinib treatment groups: 12 months and 36 months. The graph includes event and censoring markers and shows survival probabilities on the vertical axis and survival time in months on the horizontal axis.*

FDA Label Image

Spl-imatinib-fig1 (Spl Imatinib Fig1)

A Kaplan-Meier plot showing percent of patients without progression over months since randomization comparing Imatinib Mesylate and IFN+Ara-C treatments. The graph includes a table of patient numbers, hazard ratio, confidence interval, and statistical test results for progression-free survival in the two treatment arms.*

FDA Label Image

Spl-imatinib-fig2 (Spl Imatinib Fig2)

A line graph showing the percentage of patients without progression to AP or BC over time in months since randomization. It compares two treatment arms: Imatinib Mesylate and IFN+Ara-C, with Imatinib Mesylate showing higher percentages over the 72-month period. The graph includes patient numbers, hazard ratio with confidence interval, and a log-rank test p-value.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.